Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28206098 | 0.98 | RIPK1 (0.43) | RIPK1TNKSGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL20640524 | 0.80 | RIPK1 (0.44) | RIPK1HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL20096023 | 0.80 | RIPK1 (0.41) | RIPK1GAAALDH1A1SMN1; SMN2KDM1A | |
| SCHEMBL31257367 | 0.80 | RIPK1 (0.44) | RIPK1HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL20096014 | 0.78 | KDM1A (0.46) | ALDH1A1KDM1AKDM1BLMNACYP3A4 | |
| SCHEMBL28938598 | 0.77 | RIPK1 (0.40) | RIPK1TNKSGAAALDH1A1HDAC1 | |
| SCHEMBL20282506 | 0.76 | RIPK1 (0.44) | RIPK1TNKSGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL18366270 | 0.75 | CHRM2 (0.47) | HDAC1HDAC8HDAC6MEN1CYP3A4 | |
| SCHEMBL20646025 | 0.75 | CHRM2 (0.47) | HDAC1HDAC8HDAC6MEN1CYP3A4 | |
| SCHEMBL28404823 | 0.75 | RIPK1 (0.43) | RIPK1TNKSGAAALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-109843886-B | Bicyclic pyridone lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-109843886-A | Two ring pyridone lactams and its application method | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018073193-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-26 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | RIPK1 3064/4885TNKS 1340/4885GAA 968/4885 |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | RIPK1 1724/4885TNKS 513/4885GAA 2737/4885 |
| US-11072607-B2 | Inhibitors of RIP1 kinase and methods of use thereof | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885TNKS 14/4885GAA 2297/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885TNKS 14/4885GAA 2297/4885 |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | RIPK1 1724/4885TNKS 513/4885GAA 2737/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | RIPK1 3064/4885TNKS 1340/4885GAA 968/4885 |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | RIPK1 1724/4885TNKS 513/4885GAA 2737/4885 |
| US-12139482-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | RIPK1 1724/4885TNKS 513/4885GAA 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.